PranaQ set to launch TipTraQ nationwide
By HME News Staff
Updated 9:54 AM CST, Tue February 25, 2025
NEW YORK – PranaQ has received 510(k) clearance from the U.S. Food and Drug Administration for TipTraQ, a single point of contact home sleep apnea test wearable that it says provides sleep and respiratory insights with minimal disruption. With this clearance, PranaQ is set to launch TipTraQ nationwide to sleep clinics, telehealth providers and hospitals. "Receiving FDA clearance for TipTraQ is a significant milestone in our mission to revolutionize sleep diagnostics and monitoring,” said Jerry Chen, CEO of PranaQ. "With millions of undiagnosed sleep apnea sufferers, TipTraQ enables accessible and reliable at-home testing, helping more people receive timely diagnosis and treatment." PranaQ says TipTraQ is a compact wearable that uses advanced biosensors and AI algorithms to detect sleep apnea events and analyze sleep architecture with clinical-grade accuracy. The device enables patients to undergo testing from the comfort of their homes, reducing barriers to diagnosis and improving patient compliance. In addition to its comprehensive sleep parameters, TipTraQ is cleared for its ability to identify sleep apnea severity cutoffs of 5 (mild), 15 (moderate) and 30 (severe) under both the AASM 1a and 1b rules, delivering actionable insights to support well-informed clinical decisions.
Comments